WaveMan
WaveMan · Company
IMNM · Immunome Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

IMNM Immunome (IMNM) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001472012
Quote by TradingView
Form 144 · 4
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
109
13F, latest reported quarter
Conversions, 180 days
7
Codes C/M, not in net · $2.1M priced

What the filings say about IMNM

Insiders, 180 days
-$15.9M net sold
1 buyer · 6 sellers · 5% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$5.7M
4 notices

Immunome insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Immunome Inc. insiders sold a net $15.9M of stock across 61 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Higgins Jack
Chief Scientific Officer
SELL
2026-09-15 SECtraded 2026-09-11
13,200
$334.2K
-23.7%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Apr 2, 2026.
  • The trade is 20.3% of the 65,050 shares held after it.
  • 1 other insider sold within 30 days.
  • 109 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Higgins Jack sold about $334.2K of IMNM under a 10b5-1 plan on Sep 11, 2026; 1 other insider sold within 30 days and 109 funds added in the latest 13F quarter.
Barchas Isaac
Director
SELL
2026-08-12 SEC
11,048
$301.1K
-32.3%
Context
  • 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Aug 11, 2026.
  • The trade is 12.0% of the 92,211 shares held after it.
  • 2 other insiders sold within 30 days.
  • 109 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Barchas Isaac sold about $301.1K of IMNM on Aug 12, 2026; 2 other insiders sold within 30 days and 109 funds added in the latest 13F quarter.
Barchas Isaac
Director
SELL
2026-08-12 SECtraded 2026-08-11
62,291
$1.6M
-32.3%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Aug 10, 2026.
  • 1 other insider sold within 30 days.
  • 109 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Barchas Isaac sold about $1.6M of IMNM on Aug 11, 2026; 1 other insider sold within 30 days and 109 funds added in the latest 13F quarter.
Barchas Isaac
Director
SELL
2026-08-12 SECtraded 2026-08-10
10,125
$264.0K
-32.3%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Aug 7, 2026.
  • The trade is 16.3% of the 62,291 shares held after it.
  • 1 other insider sold within 30 days.
  • 109 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Barchas Isaac sold about $264.0K of IMNM on Aug 10, 2026; 1 other insider sold within 30 days and 109 funds added in the latest 13F quarter.
Barchas Isaac
Director
SELL
2026-08-10 SECtraded 2026-08-07
15,248
$397.4K
-31.8%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Aug 6, 2026.
  • The trade is 21.1% of the 72,416 shares held after it.
  • 1 other insider sold within 30 days.
  • 109 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Barchas Isaac sold about $397.4K of IMNM on Aug 7, 2026; 1 other insider sold within 30 days and 109 funds added in the latest 13F quarter.
61 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 56 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$15.9M over 180 days
-$5.7M over 90 days
below 87% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
109 funds bought in last quarter
more than 72% of Pharma & Biotech
Revenue
-23.2% year over year
below 70% of Pharma & Biotech
Margin
-3060.0% net margin
below 94% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
15.4% of the float short (float per yahoo 2026-10-26) · 9.9 days to cover · settled 2026-09-30
more than 84% of Pharma & Biotech
What changed in the last 30 days
Oct 28Insider buying stopped: no purchases in 90 days after 4 in the prior 90
Why it matters
The absence is the signal: 4 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch IMNM

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+11.4%12M
-5%+25%+55%+86%2025-102025-122026-022026-042026-062026-082026-10 2025-12-22 · Barchas Isaac sold $8.1M2026-08-04 · Horn Kinney sold $2.3M2026-06-30 · Barchas Isaac sold $2.1M2026-07-06 · Barchas Isaac sold $2.0M2026-07-02 · Barchas Isaac sold $1.7M2026-08-11 · Barchas Isaac sold $1.6M2026-04-02 · Rosett Max sold $1.4M2026-06-15 · Rosett Max sold $1.1M2025-12-18 · SIEGALL CLAY B bought $1,000.0K2026-06-25 · Lechleider Robert sold $793.7K2026-03-20 · WAGENHEIM PHILIP sold $753.3K2026-03-23 · WAGENHEIM PHILIP sold $582.3K2026-07-02 · Barchas Isaac sold $567.7K2026-08-06 · Barchas Isaac sold $543.1K2026-03-27 · SIEGALL CLAY B bought $500.6K2026-07-02 · Lechleider Robert sold $498.6K2026-07-07 · Barchas Isaac sold $409.1K2026-08-07 · Barchas Isaac sold $397.4K2026-07-02 · Lechleider Robert sold $376.7K2026-07-02 · Lechleider Robert sold $369.0K2026-09-11 · Higgins Jack sold $334.2K2026-08-12 · Barchas Isaac sold $301.1K2026-06-25 · Lechleider Robert sold $297.9K2026-08-10 · Barchas Isaac sold $264.0K2025-12-22 · Barchas Isaac sold $251.3K2025-12-19 · Tsai Philip bought $204.9K2026-04-02 · Higgins Jack sold $204.2K2026-06-05 · BIENAIME JEAN JACQUES sold $194.1K2025-12-19 · SIEGALL CLAY B bought $149.1K2026-06-05 · BIENAIME JEAN JACQUES bought $116.9K2026-05-15 · BIENAIME JEAN JACQUES bought $103.5K2025-12-30 · SIEGALL CLAY B bought $100.0K2026-06-05 · BIENAIME JEAN JACQUES bought $68.1K2026-04-02 · Rosett Max sold $30.2K2026-07-07 · Horn Kinney sold $27.3K2026-03-10 · BIENAIME JEAN JACQUES bought $22.1K2026-03-11 · BIENAIME JEAN JACQUES bought $21.6K2026-06-05 · BIENAIME JEAN JACQUES bought $19.3K2026-06-05 · BIENAIME JEAN JACQUES sold $9.7K2026-09-11 · Higgins Jack filed to sell $334.2K2026-08-12 · Barchas Isaac filed to sell $301.1K2026-08-06 · ABHMC II, LLC filed to sell $2.8M2026-08-04 · Horn Kinney filed to sell $2.3M2026-07-07 · Horn Kinney filed to sell $27.3K2026-07-06 · ABHMC II, LLC filed to sell $2.4M2026-07-02 · ABHMC II, LLC filed to sell $2.1M2026-07-02 · Lechleider Robert filed to sell $1.2M2026-06-30 · ABHMC II, LLC filed to sell $2.1M2026-06-30 · Arsenal Bridge Venture II-B, LLC filed to sell $22.1K2026-06-25 · Lechleider Robert filed to sell $1.1M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns IMNM: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
16,987,553 sh
$360.0M
BlackRock, Inc.
8,805,492 sh
$186.6M
STATE STREET CORP
5,494,625 sh
$116.4M
WELLINGTON MANAGEMENT GROUP LLP
5,210,216 sh
$110.4M
Redmile Group, LLC
4,911,590 sh
$104.1M

Congress trades in IMNM

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

IMNM planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Higgins Jack
Filed 2026-09-11
$334.2K
Barchas Isaac
Filed 2026-08-12
$301.1K
ABHMC II, LLC
Filed 2026-08-06
$2.8M
Horn Kinney
Filed 2026-08-04
$2.3M
Horn Kinney
Filed 2026-07-07
$27.3K

IMNM mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Tema Oncology ETF
$6.9M position · as of 2026-05-31
3.9%
T. Rowe Price Institutional Small-Cap Stock Fund
$82.8M position · as of 2026-06-30
1.6%
T. Rowe Price Small-Cap Stock Fund, Inc.
$152.1M position · as of 2026-06-30
1.6%
T. Rowe Price Health Care ETF
$318.0K position · as of 2026-06-30
1.4%
PRIMECAP Odyssey Aggressive Growth Fund
$84.1M position · as of 2026-07-31
1.1%
Driehaus Micro Cap Growth Fund
$6.5M position · as of 2026-06-30
1.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
11 registered trials, 6 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
10
Phase 1
5 active
1
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $15.9M sold by insiders over 180 days, 109 funds added last quarter, $5.7M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

IMNM financials

Revenue growth
-23.2%
XBRL, annual
Net margin
-3060.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
-$219.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.00x
long-term 2021-03-31 (63 months older than the period end) plus current 2021-03-31 (63 months older than the period end); equity 2026-06-30
Cash flow to debt
-417.59x
TTM operating cash flow over long-term 2021-03-31 (63 months older than the period end) plus current 2021-03-31 (63 months older than the period end)
Return on equity
-64.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-59.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-67.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$1.8B
market value at close 2026-10-26 on 2026-08-06 shares, plus long-term 2021-03-31 (63 months older than the period end) plus current 2021-03-31 (63 months older than the period end), minus cash 2026-06-30
FCF yield
-10.8%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$6.9M$9.0M$14.0Mn/a
Operating income-$224.1M-$305.8M-$109.5M-$36.9M
Net income-$212.4M-$293.0M-$106.8M-$36.9M
EPS (diluted)-2.43-5.00-5.38-3.09
Operating cash flow-$190.9M-$110.8M-$7.6M-$28.7M
Cash$653.5M$143.4M$98.7M$20.3M
SEC XBRL, fiscal years, as known on 2026-10-28

IMNM Stock Sonar score 6/7 axes

Find similar shapesCompare

IMNM ranks highest on institutional and government (72nd percentile) and financial health (44th), and lowest on growth (30th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
41
Inputs
  • Return on equity-64.0% · 46 pct, sector of 545
  • Return on assets-59.0% · 39 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-67.4% · 37 pct, sector of 576
Financial health
44
Inputs
  • Debt to equity0.00x · 85 pct, sector of 352
  • Cash flow to debt-417.59x · 3 pct, sector of 371
Growth
30
Inputs
  • Revenue growth, YoY-23.2% · 30 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
34
Inputs
  • Net Form 4 buying (codes P and S), 180d-$15.6M · 11 pct, sector of 428
  • Insider buyers, 180d1 · 56 pct, sector of 437
Institutional and government
72
Inputs
  • Funds adding, latest quarter109 · 72 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
40
Inputs
  • Short interest, % of float+15.4% · 25 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+9.8% · 55 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

IMNM filings, in plain words

Are Immunome insiders buying or selling IMNM?

In the 180 days to 2026-10-28, Immunome insiders were net sellers, a net $15.9M: $307.8K of purchases and $16.2M of sales reported on Form 4, by 1 buyer and 6 sellers.

Are there planned insider sales of IMNM?

Yes. 4 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $5.7M of stock; the latest, by Higgins Jack, was filed 2026-09-11.

Read the full summary

In the 180 days to 2026-10-28, Immunome insiders were net sellers of IMNM, a net $15.9M across purchases and sales reported on Form 4 by 1 buyer and 6 sellers. Sales outweighed purchases more than tenfold by value. 5% of the 21 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 4 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $5.7M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies